CoERG11 A395T mutation confers azole resistance in Candida orthopsilosis clinical isolates | Zendy

Cosmeri Rizzato | Zendy; Noemi Poma | Zendy; Marina Zoppo | Zendy; Brunella Posteraro | Zendy; Enrica Mello | Zendy; Daria Bottai | Zendy; Antonella Lupetti | Zendy; Maurizio Sanguinetti | Zendy; Arianna Tavanti | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

CoERG11 A395T mutation confers azole resistance in Candida orthopsilosis clinical isolates

Author(s) -

Cosmeri Rizzato,

Noemi Poma,

Marina Zoppo,

Brunella Posteraro,

Enrica Mello,

Daria Bottai,

Antonella Lupetti,

Maurizio Sanguinetti,

Arianna Tavanti

Publication year - 2018

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dky122

Subject(s) - azole , biology , fluconazole , mutant , genetics , microbiology and biotechnology , gene , antifungal

Candida orthopsilosis is a human fungal pathogen responsible for a wide spectrum of symptomatic infections. Evidence suggests that C. orthopsilosis is mainly susceptible to azoles, the most extensively used antifungals for treatment of these infections. However, fluconazole-resistant clinical isolates are reported.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research